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ABSTRACT Rabies kills many people throughout the
developing world every year. The murine monoclonal
antibody (mAb) 62-71-3 was recently identified for its
potential application in rabies postexposure prophy-
laxis (PEP). The purpose here was to establish a
plant-based production system for a chimeric mouse-
human version of mAb 62-71-3, to characterize the
recombinant antibody and investigate at a molecular
level its interaction with rabies virus glycoprotein. Chi-
meric 62-71-3 was successfully expressed in Nicotiana
benthamiana. Glycosylation was analyzed bymass spectros-
copy; functionality was confirmed by antigen ELISA, as
well as rabies and pseudotype virus neutralization.
Epitope characterization was performed using pseu-
dotype virus expressing mutagenized rabies glycopro-
teins. Purified mAb demonstrated potent viral neutraliza-
tion at 500 IU/mg. A critical role for antigenic site I of the
glycoprotein, as well as for two specific amino acid
residues (K226 andG229) within site I, was identified with
regard to mAb 62-71-3 neutralization. Pseudotype viruses
expressing glycoprotein from lyssaviruses known not to
be neutralized by this antibody were the controls. The
results provide the molecular rationale for developing
62-71-3 mAb for rabies PEP; they also establish the basis
for developing an inexpensive plant-based antibody prod-
uct to benefit low-income families in developing coun-
tries.—Both, L., van Dolleweerd, C., Wright, E., Banyard,
A. C., Bulmer-Thomas, B., Selden, D., Altmann, F., Fooks,
A. R., Ma, J. K.-C. Production, characterization, and
antigen specificity of recombinant 62-71-3, a candidate
monoclonal antibody for rabies prophylaxis in humans.
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Rabies has the highest human case:fatality ratio of
all infectious diseases, and it is widely accepted that
there is no effective treatment after onset of symptoms
(1–3). The causative agent is a negative-stranded RNA
virus in the order Mononegavirales, family Rhabdoviridae,
genus Lyssavirus (4). All mammals are susceptible and
can transmit rabies virus (RV; ref. 5), and both canine
and sylvatic (wildlife) circulation patterns are recog-
nized (6). Most human exposures are associated with
the bites of rabid animals, in particular, unvaccinated
dogs, and transmission of RV in their saliva (7). Human
rabies cases have also been attributed to probable
aerosol exposures in laboratories or airborne exposures
in caves with high densities of bats (8, 9). In addition,
atypical transmission through butchering and process-
ing of rabid animals, as well as human-to-human trans-
mission by organ or tissue transplantation have been
reported (10, 11).
Although viral spread to the central nervous system
(CNS) and resulting encephalitis are almost invariably
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fatal, the disease is preventable through postexposure
prophylaxis (PEP). Swift administration of PEP is virtu-
ally 100% effective in preventing the onset of symptoms
and fatal clinical disease after exposure (12–17). Rabies
PEP is based on 3 pillars: wound cleansing, administra-
tion of rabies vaccine, and infiltration of rabies immu-
noglobulins (RIGs) of either human or equine origin
(HRIGs or ERIGs, respectively). However, insufficient
access to RIGs restricts the administration of appropri-
ate PEP across the developing world where the vast
majority of the annual 55,000–70,000 rabies fatalities
occur (18–22). To overcome the short supply and the
safety issues with blood-derived RIG products, several
human and murine monoclonal antibodies (mAbs) are
being investigated (23–25). A recent report by the
World Health Organization (WHO) Rabies Collaborat-
ing Centres described the identification of three novel
combinations of mAbs to replace RIGs (6). Stringent
criteria concerning the neutralizing activity, binding
specificities to different epitopes, immunoglobulin
isotype, and history of hybridomas were used to
evaluate the suitability of several murine mAbs. Com-
binations of 2 mAbs, all including mAb 62-71-3, were
assessed both in vitro and in vivo and were shown to
have an equal or superior efficiency to HRIGs in the
hamster PEP model (6).
The objective of the present study was to clone and
express a chimeric (mouse-human) full-length IgG1
version of mAb 62-71-3, using plants as an inexpensive
production alternative to existing mammalian systems,
and to perform a detailed molecular characterization
of the recombinant mAb. Initially, a phage-displayed
single-chain variable fragment (scFv) of mAb 62-71-3
was expressed in Escherichia coli and tested to confirm
that the sequences for heavy and light chains cor-
rectly encoded for an antibody with neutralizing
potency toward the virus. A chimeric 62-71-3 full-
length IgG was then cloned, expressed, and purified
from Nicotiana benthamiana leaves. The plant-derived
mAb was investigated using mass spectrometry for
glycan analysis, RV glycoprotein enzyme-linked im-
munosorbent assay (ELISA), fluorescent antibody
virus neutralization (FAVN) and pseudotype neutral-
ization assay (PNA). Mutations in antigenic site I of the
RV glycoprotein severely diminished neutralization by
mAb 62-71-3, pointing to an important role of this
epitope in the binding between the viral glycoprotein
and the plant-derived antibody.
The work presented here confirms the molecular
rationale of using mAb 62-71-3 as part of a mAb cocktail
for rabies PEP. It also highlights the feasibility of using
plants for the inexpensive production of mAbs for
developing countries (26, 27). Plants constitute an
economically feasible production platform that can
easily be scaled up and that is amenable for transfer to
the developing world (28). As plants are eukaryotic
organisms, they possess a similar intracellular machin-
ery to that of mammalian cells, so that complex pro-
teins like antibodies are correctly folded and assembled
(29, 30).
MATERIALS AND METHODS
Cloning and expression of the 62-71-3 phage-displayed scFv
mAb 62-71-3 is a hybridoma-derived IgG2b antibody, origi-
nally generated by immunizing BALB/c mice with the rabies
vaccine strain ERA (6, 31). The cDNA sequences for the
variable regions of mAb 62-71-3 were received from Apotech
(Lausanne, Switzerland). To confirm cloning of the correct
variable region sequences, an scFv version of mAb 62-71-3 was
initially expressed in E. coli. The variable regions of heavy and
light chains were amplified by PCR and were connected with
a flexible 15-aa linker, using the primers listed in Table 1 and the
cloning strategy described in Supplemental Data. A schematic
representation of the cloning strategy is shown in Fig. 1A.
Cloning and expression of chimeric mAb 62-71-3
The murine variable regions of mAb 62-71-3 were grafted on
the constant regions of a human mAb (IgG1 ), using the
primers listed in Table 2 and the cloning strategy described in
Supplemental Data. A schematic representation of the clon-
ing strategy is shown in Fig. 1B. The heavy and light chain
sequences of the chimeric 62-71-3 were then shuttled from
the entry vector pDONR into the Gateway destination vector
pEAQ-HT-Dest3 for expression in plants (32) or with the
Gateway destination vectors pcDNA-Dest40 and pEF-Dest51 (In-
vitrogen, Carlsbad, CA, USA) for expression in mammalian
cells. Agrobacterium tumefaciens cultures (strain LBA4404) trans-
formed with either the heavy-chain or light-chain vectors were
each adjusted to optical density at 600 nm (OD600)  1 by
diluting the cells with infiltration buffer (10 mM MES and 10
mM MgCl2, pH 5.6) and combined. The cells were incubated in
the dark (2 h, room temperature) before infiltration of N.
benthamiana plants with a 1-ml syringe without needle (2–3
leaves/plant). Soluble leaf extracts were prepared by grinding
leaf tissue in a mortar and centrifugation.
The HEK293-derived mAb 62-71-3 was generated by mixing
1 g of the heavy- and light-chain plasmids with Fugene 6
(Roche, Basel, Switzerland) according to manufacturer’s in-
structions and transfection of 70% confluent 293T-17 cells in
a 6-well plate containing 2 ml medium/well (DMEM plus
15% FBS and 1% Pen/Strep). The plates were incubated at
37°C (5% CO2), and medium was changed after 24 h. After
TABLE 1. PCR primers for cloning the phage-displayed 62-71-3 scFv
Fragment Primer
62-71-3H#14 ctatgcggcccagccggccatggctcaggtgcagctgaaggagtca
62-71-3H#10 accgctgccaccaccgccggagccaccgccacctgaggagactgtgagagtggt
62-71-3L#7 tccggcggtggtggcagcggtggcggcggttctgatgtccagatgacacagact
62-71-3L#6 tggtgctgcggccgcccgttttatttccagcttggtccc
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2–3 d, the supernatants were collected, passed through a
0.45-m filter, and stored at 4°C.
SDS-PAGE and Western blot analysis
The soluble fraction of a plant extract was passed through
Miracloth (EMD Millipore, Billerica, MA, USA) and a
0.45-m filter, and the mAb was purified by protein G (Sigma,
Gillingham, UK) affinity chromatography. Both the purified
mAb and the crude plant extract were analyzed by SDS-PAGE
and semidry Western blot analysis. SDS-PAGE was performed
using the Invitrogen Minigel system and Invitrogen NuPAGE
buffers. Electrophoresis was carried out in 4–12% gradient
gels (Invitrogen), which were stained with Coomassie brilliant
blue or subjected to Western blotting. Transfer to the mem-
brane (Amersham Hybond-ECL; Amersham Biosciences, Lit-
tle Chalfont, UK) was carried out in a semidry system (Invit-
rogen). The membrane was blocked with milk (3%),
incubated with horseradish peroxidase (HRP)-coupled anti-
bodies at a concentration of 1:10,000, and developed (Amer-
sham ECL Plus Western blotting detection kit, Amersham
Hyperfilm ECL).
RV glycoprotein ELISA
A commercial ELISA kit (Bio-Rad Platelia Kit; Bio-Rad,
Hemel Hempstead, UK) was used to investigate recombinant
antibody binding to its target antigen. The ELISA is based on
RV glycoprotein coated on the plate and detection of anti-
body using HRP-coupled protein A. Clarified plant extract
supernatants (at 3, 5, and 7 d postinfiltration) were applied to
the wells, and the assay was run according to the manufactur-
er’s instructions.
The RV glycoprotein ELISA was also used for competi-
tion experiments, as described recently (33), with minor
modifications. Briefly, plates were incubated with saturat-
ing amounts of purified plant-derived mAbs 62-71-3 and
E559 for 1 h at room temperature. For the initial produc-
tion of the plant-derived mAb E559, the E559 hybridoma
was obtained from Dr. Thomas Müller [Friedrich Loeffler
Institut(FLI), Wusterhausen, Germany; ref. 6). The hybrid-
oma heavy- and light-chain sequences for this murine IgG1
antibody were obtained by RT-PCR, engineered into chi-
meric mouse-human sequences, and cloned into the plant
expression vector pL32. The chimeric heavy- and light-
chain sequences of mAb E559 were then coexpressed in N.
benthamiana by agroinfiltration and purified as described
above for mAb 62-71-3.
For the competition experiment, the hybridoma-derived
mAb E559 was biotinylated with the No-Weigh Sulfo-NHS-LC-
Biotin (Pierce, Rockford, IL, USA), according to manufactur-
er’s instructions, and 50 l of biotinylated mAb E559 (2.5
g/ml) was then added to each well, incubated for 5 min at
room temperature, and rinsed 5 times with 100 l of Tris-
buffered saline with 0.1% Tween (TBST). Subsequently, wells
were incubated for 1 h at room temperature with 50 l of a
1:5,000 dilution of streptavidin-HRP (Sigma). Wells were
rinsed, and HRP activity was detected by the addition of
3,3=,5,5=-tetramethylbenzidine dihydrochloride substrate (Sigma).
Color development was allowed to proceed for 10 min at
room temperature before the addition of 2 M H2SO4 to
terminate the reaction. The OD was measured at 450 nm on
an ELISA plate reader.
Generation of lentiviral pseudotype viruses
DNA plasmids encoding the HIV gag-pol, luciferase reporter
gene, and lyssavirus glycoproteins were used as previously
reported (33). Briefly, pseudotype viruses were generated by
mixing 1 g of the HIV gag-pol plasmid, 1 g of the
glycoprotein plasmid, and 1.5 g of the reporter gene plas-
mid with Fugene 6 (Roche) and transfection of 70% conflu-
ent 293T-17 cells in a 6-well plate containing 2 ml medium/
well (DMEM plus 15% FBS and 1% Pen/Strep). The plates
were incubated at 37°C (5% CO2), and medium was changed
after 24 h. After 2 d, the supernatants containing pseudotype
virus were collected, passed through a 0.45-m filter, and
frozen at 80°C.
PNA
The concentration of the purified plant-derived mAb was
measured with the bicinchoninic acid (BCA) protein assay
kit (Pierce). The phage-displayed 62-71-3 scFv or plant-
derived 62-71-3 IgG (5 g/ml) was added to medium
(DMEM plus 10% FCS and 1% Pen/Strep) and titrated in
doubling dilutions across a 96-well plate, starting with a
1:10 or 1:20 dilution (final volume of 50 l/well). Controls
were cells only, virus only, and cells and virus, which were
set up with appropriate amounts of medium. Pseudotype
virus (50 l) was added to each well (apart from cells-only
control) at a dilution where the international reference
serum (OIE serum) neutralizes 100% at 1:40 serum
dilution [100 median tissue culture infective dose
(TCID50)]. The plate was centrifuged (500 rpm, 5 s) and
incubated at 37°C (5% CO2) for 1 h. Medium (100 l)
containing 2  104 BHK cells was added to each well (apart
from virus-only control), making up a total volume of 200
l/well. The plate was centrifuged (500 rpm, 5 s) and
incubated at 37°C (5% CO2) for 48 h. Medium (115 l) was
removed from each well, and 75 l BrightGlo (Promega,
Madison, WI, USA) was added. After measuring absolute
infection (light units) by the pseudotype virus with a
TABLE 2. PCR primers for cloning the 62-71-3 IgG
Fragment Primer
attB1-OryzaLS#2 ggggacaagtttgtacaaaaaagcaggctcaaccatggggaagcaaatggccgccctgtgtggctttctc
OryzaLS#1 agcaaatggccgccctgtgtggctttctcctcgtggcgttgctctggctcacgcccgacgtc
LB01 cgttgctctggctcacgcccgacgtcgcgcatggtcaggtgcagctgaaggagtca
LB02 accgatgggcccttggtggaggctgaggagactgtgagagtggt
LB03 accactctcacagtctcctcagcctccaccaagggcccatcggt
4E10H#15 ggggaccactttgtacaagaaagctgggtctttacccggagacagggagaggct
LB04 cgttgctctggctcacgcccgacgtcgcgcatggtgatgtccagatgacacagact
LB05 acagatggtgcagccacagtccgttttatttccagcttggt
LB06 accaagctggaaataaaacggactgtggctgcaccatctgt
4E10L#9 ggggaccactttgtacaagaaagctgggtcggtacctaacactctcccctgttgaagctcttt
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luminometer, the relative neutralization was calculated,
and titration curves were generated.
FAVN assay
The standard FAVN test was set up in a similar way to the
PNA, starting with a 1:8 dilution of antibody. OIE and OIE
sera were included as controls for CVS. To assess neutraliza-
tion of other lyssaviruses, a modified FAVN was performed as
described previously (63). Briefly, for each sample, mAbs and
the viruses were incubated at 37°C (5% CO2) for 1 h before
adding 4  105 BHK cells to each well. The plates were then
incubated at 37°C (5% CO2) for 48 h, fixed in 80% acetone,
and air-dried. The staining was carried out by adding 50 l of
fluorescein isothiocyanate (FITC)-conjugated antibody (Cen-
tocor, Philadelphia, PA, USA), specific for the RV nucleopro-
tein, to each well. After a 30-min incubation at 37°C (5%
CO2), each plate was washed 3 times with PBS. Excess PBS was
removed by briefly inverting the microplates on absorbent
paper, and the neutralizing titer was evaluated by fluorescent
microscopy.
Glycan analysis of the plant-derived mAb 62-71-3
A glycoproteomic analysis was undertaken by in-gel digestion
of S-carbamidomethylated sample and analysis by reverse-
phase electrospray ionization mass spectrometry (RP-ESI-
MS), as described previously (63). Tandem MS results were
also subjected to Mascot MS/MS ion search (Matrix Science
Ltd., London, UK; http://www.matrixscience.com).
Mutational analysis of the RV glycoprotein
Chimeric RV/Lagos bat virus (LBV) glycoproteins were gen-
erated by swapping antigenic sites I–IV of the RV strain CVS11
(accession no. EU352767) with those of LBV strain Nig56-
RV1 (accession no. EF547431). Moreover, glycoproteins con-
taining either a K226R, G229E, or N336S mutation within
antigenic site I were generated by site-directed mutagenesis,
using the cloning primers 5=-GCGCGCGGTACCGCCAC-
CATGGTTCCTCAGGTTCTT-3= and 5=-GCGCGCCTCGAGT-
TACAGTCTGATCTCACCTC-3=, annealing to opposite ends
of the CVS11 glycoprotein. Mutagenesis primers were 5=-
ATGCAGGCTCAGGTTATGTGGAG-3= (forward) and 5=-CTCC-
ACATAACCTGAGCCTGCAT-3= (reverse) for the K226R mu-
tation within antigenic site I, 5=-CAAGTTATGTGAAGTACT-
TGGACTTAG-3= (forward) and 5=-CTAAGTCCAAGTACTTCA-
CATAACTTG-3= (reverse) for the G229E mutation within anti-
genic site I, and 5=-TCCGGACCTGGAGTGAGATCATCC-3= (for-
ward) and 5=-GGATGATCTCACTCCAGGTCCGGA-3= (reverse)
for the N336S mutation within antigenic site III. All mutated
glycoproteins were shuttled into the plasmid pl18 via KpnI
and XhoI restriction sites and expressed on the surface of
lentiviral pseudotype viruses, as described above. Neutraliza-
tion assays with these pseudotypes were undertaken by prein-
cubating the phage-displayed 62-71-3 scFv or the plant-de-
rived 62-71-3 IgG (1 g/ml) with the pseudotypes before
adding the BHK cells, as described above. Controls were cells
only, virus only, cells and virus, and the plant-derived mAb
E559, known to be directed against antigenic site II of the
viral glycoprotein.
RESULTS
Characterization of phage-displayed 62-71-3 scFv
The cDNA sequences for the variable regions of the
heavy and light chains of mAb 62-71-3 were cloned into
a phagemid vector (Fig. 1A) to verify that the sequences
correctly encoded for an antibody with neutralizing
potency toward the virus. The phage-displayed 62-71-3
scFv was tested for its neutralization of a lentivirus
(HIV) pseudotyped with the RV glycoprotein (strain
CVS11) and demonstrated potent, dose-dependent
neutralization of the pseudotype virus (Fig. 2A), con-
firming that the correct heavy and light chains were
cloned. Controls included a nonspecific scFv (Fig. 2A),
as well as cells only, virus only, and cells and virus (data
not shown).
Production and antigen-binding properties of plant-
derived chimeric mAb 62-71-3
After the initial neutralization experiments with the
62-71-3 scFv, a chimeric antibody was constructed (Fig.
1B) and expressed in N. benthamiana. Infiltrated N.
benthamiana leaves showed robust expression of 62-71-3
IgG (estimated as 3–4% of total soluble protein by
Figure 1. Schematic representation of the con-
structs used in this study. A) Scheme of the
phage-displayed 62-71-3 scFv for expression in
E. coli. B) Scheme of the heavy and light chains
of mAb 62-71-3 for expression in N. benthami-
ana. Primers and their relative location/orien-
tation are indicated with black arrows.
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quantitative ELISA and in excess of 100 mg/kg fresh
tissue). The antibody was purified from the soluble
plant extract fraction by affinity chromatography with
protein G, which binds the human Fc region of the
chimeric antibody heavy chain. The crude plant extract
and the purified antibody were analyzed by nonreduc-
ing SDS-PAGE and Western blot analysis (Fig. 2B).
Probing Western blots with an anti-HC antibody re-
vealed the presence of mAb 62-71-3 in plant extracts
and in the purified samples. The corresponding band
was also detected in HEK293 supernatants after
cotransfection with the 62-71-3 heavy- and light-chain
vectors (Fig. 2B).
To confirm the specific antigen recognition of the
plant-derived mAb, a functional ELISA was performed
on plant extracts harvested at different time points after
agroinfiltration. Samples derived from infiltrated leaves
demonstrated specific binding to the RV glycoprotein,
while samples derived from wild-type leaves showed no
relevant antigen binding (Fig. 2C). This experiment
confirmed that mAb 62-71-3 was correctly assembled in
planta and that substituting the original murine anti-
body Fc region with its human counterpart did not
abrogate its antigen-binding activity.
Neutralization of live viruses and pseudotype viruses
The plant-derived 62-71-3 IgG was tested for its neutral-
ization of a rabies pseudotype virus (strain CVS11) and
demonstrated potent neutralization (Fig. 2D). The
concentration of the purified plant-derived mAb was
measured with the bicinchoninic acid (BCA) protein
assay kit (Pierce). A nonspecific IgG had no neutraliz-
ing activity. The plant-derived 62-71-3 also demon-
strated excellent specific neutralization activity against
BBLV, KELEV, and an E559 mAb escape mutant (6),
weak neutralization against Pasteur virus, but no neu-
tralization of Duvenhage virus or LBV (data not
shown).
The breadth of neutralization was further investi-
gated using lentiviruses pseudotyped with a panel of
lyssavirus glycoproteins from different phylogroup I
viruses and some related Eurasian lyssaviruses. In addi-
tion to the CVS11 strain, the plant-derived IgG demon-
strated potent neutralization of several different lyssa-
viruses, including ERA (RV), RV1787, and RV634
(Fig. 3A, B). Diminished neutralization was observed
for the two Duvenhage virus strains SA06 and RV131
(Fig. 3B) and the two European bat lyssavirus type 1
strains RV9 and RV20 (Fig. 3A). The three Eurasian
lyssaviruses Irkut, Khujand, and Aravan were all
strongly neutralized (Fig. 3C). We also tested RV
neutralization by the plant-derived purified mAb with
the FAVN assay. The plant-derived antibody demon-
strated a neutralizing titer of 500 IU/mg for strain
CVS11, while no neutralization was observed for LBV,
an RV-related phylogroup II virus (negative control).
Glycoproteomic analysis
Sequence analysis of heavy and light chains of mAb
62-71-3 predicted the presence of a single potential
N-linked glycosylation site in the antibody Fc region.
The plant-derived antibody was subjected to glycopro-
teomic analysis by RP-ESI-MS. Glycopeptides compris-
ing the Fc glycosylation site EEQYNSTYR (N-linked
glycosyation site is underscored) were identified at the
early retention time characteristic for this peptide (44,
63). The glycan analysis revealed that mAb 62-71-3
displayed glycan compositions typical of plant glycopro-
teins, with predominantly complex type glycans con-
taining xylose and fucose, which are presumed to be
the 1,2-linked xylose residues attached to the -linked
mannose and the 	1,3-fucose residue linked to the
Asn-linked N-acetyl-glucosamine (Fig. 4). Tandem MS
results were subjected to Mascot MS/MS ion search,
which confirmed the sample to contain essentially mAb
62-71-3.
Figure 2. Pseudotype virus neutralization by the 62-71-3 phage-displayed scFv and
the plant-derived IgG. A) Titration curve showing the pseudotype virus neutral-
ization by the phage-displayed 62-71-3 scFv and by a phage-displayed nonspecific
scFv (control). B) SDS-PAGE (left panel) and Western blotting (middle and right
panels) under nonreducing conditions. M denotes Coomassie gel with molecular
mass marker in kDa. Lane 1, purified plant-derived 62-71-3 IgG; lane 2, plant
extract from infiltrated plants; lane 3, plant extract from wild-type plants. C
denotes control with HEK293-derived mAb 62-71-3. The Western blot was probed
with an anti-human HC-specific antibody (Sigma). C) RV glycoprotein ELISA with plant samples harvested at various days
post infiltration (dpi). D) Titration curve showing the pseudotype virus neutralization by the plant-derived 62-71-3 IgG and
by a nonspecific IgG (control). Titrations were repeated 2 times; each panel shows one representative run.
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Competition ELISA
To verify that the binding of mAb 62-71-3 does not depend
on antigenic site II, the immunodominant epitope in mice,
a competition experiment with the site II-specific mAb E559
was performed, using a protocol adopted from Marissen et al.
(34). RV glycoprotein ELISA plate wells were incubated with
saturating amounts of purified plantibodies before adding
biotinylated hybridoma-derived mAb E559. As expected, the
binding of biotinylated E559 was blocked when plates were
preincubated with plant-derived mAb E559 (Fig. 5). In
contrast, binding was not blocked when the 62-71-3
plant-derived antibody or no antibody (buffer only,
negative control) were added, indicating that mAb
62-71-3 does not compete with the site II-specific
mAb E559.
Mutational analysis of the RV glycoprotein
To investigate the antibody-antigen interaction in more
detail, a set of RV glycoprotein mutants was analyzed
regarding their neutralization by the 62-71-3 scFv.
These mutants were based on CVS11 pseudotype vi-
ruses, each containing a separate replacement of one of
the 4 major antigenic sites by the corresponding region
from a phylogroup II virus (LBV.Nig56-RV1). The
neutralization experiments with these mutated pseu-
dotypes showed that neutralization by the 62-71-3 scFv
was severely diminished when antigenic site I was
altered (Fig. 6A). In contrast, mutations in other anti-
genic sites did not diminish neutralization by the
62-71-3 scFv. A similar experiment was undertaken with
the plant-expressed 62-71-3 IgG (Fig. 6B). To demon-
strate that the effects of mutating antigenic site I were
specific for neutralization by mAb 62-71-3, we also
included the plant-derived mAb E559, which targets
antigenic site II of the viral glycoprotein (6). This
chimeric version of mAb E559 was also cloned and
expressed in planta (unpublished results) and purified
from plant leaves by protein G affinity chromatography,
for a direct comparison with the plant-derived purified
62-71-3 IgG. While mAbs E559 and 62-71-3 both showed
potent and complete neutralization of a rabies pseu-
dotype virus containing the CVS11 wild-type glycopro-
tein (CVS control), only mAb 62-71-3 showed dimin-
ished neutralization of the pseudotype virus containing
the CVS11 glycoprotein mutated in site I, and a 100%
neutralizing titer could not be defined for this mutant.
Amino acid residues present in antigenic site I were
then compared for the lyssavirus pseudotypes assessed.
Antigenic site I comprises 6 amino acid residues at
positions 226–231 of the mature viral glycoprotein
(without signal peptide). Alignments of the antigenic
site I sequences from the different glycoproteins used
in Fig. 3 and 4 revealed conservation of the 3 core
amino acids L227, C228, and G229 (Table 3). However,
whereas lyssavirus genotypes containing the residue
K226 within antigenic site I were completely neutral-
ized by mAb 62-71-3, lyssaviruses containing R226
showed diminished neutralization, and no 100% neu-
tralizing titer could be defined for this point mutant
(Fig. 6C). To confirm the critical role of residue K226,
we investigated the 2 plant-derived mAbs 62-71-3 and
Figure 3. Neutralization of different lyssavirus pseudotypes by the
plant-derived 62-71-3 IgG.A) Neutralization of RV (strain ERA) and
DUVV (strains SA06, RV131). B) Neutralization of EBLV1 (strains
RV9, RV20), EBLV2 (strain RV1787), and ABLV (strain RV634).C)
Neutralization of the Eurasian lyssaviruses. Titrations were repeated
2 times; each panel shows one representative run.
Figure 4. Glycoproteomic analysis of the plant-derived 62-71-3
IgG by in-gel digestion of S-carbamidomethylated sample and
RP-ESI-MS. Deconvoluted spectrum of the glycopeptide elu-
tion region of the Fc glycopeptide. Masses correspond to
oligomannosidic (Man7 etc.) and complex-type structures.
Squares, circles, stars, and triangles represent N-acetylgluco-
samine, mannose, xylose, and fucose, respectively.
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E559 regarding their neutralization of pseudotypes
containing glycoproteins with a K226R (lysine to argi-
nine) mutation (Fig. 6D). Controls included pseu-
dotypes containing the CVS11 wild-type glycoprotein or
containing the CVS11 glycoprotein harboring a non-
specific mutation in antigenic site III residue N336,
which has previously been found to be critical for
neutralization by mAbs targeting site III (24, 57). This
residue was mutated to the serine found in LBV
(N336S) and had no effect on neutralization by mAb
62-71-3 (Fig. 6C). In contrast, the K226R mutation
diminished neutralization and confirmed the critical
role of this residue for neutralization by mAb 62-71-3
(Fig. 6C). We also investigated the glycine residue
(G229) that is part of the conserved region of antigenic
site I. This residue has previously been found mutated
in viral escape mutants resistant to a mAb-targeting
antigenic site I (34), so we prepared CVS11 pseudotype
virus harboring a G229E point mutation that corre-
sponds to the escape mutant previously described (34).
Similar to the K226R mutation, diminished neutraliza-
tion by mAb 62-71-3 was observed with the G229E
mutation, but not for mAb E559 (Fig. 6D).
DISCUSSION
Rabies occurs mainly among low-income families in
Africa and Asia, and an inexpensive antibody product
would be highly desirable for implementing appropri-
ate PEP. Because of high costs and short supply,
replacement of plasma-derived HRIGs and ERIGs re-
mains a priority (35, 36), and a useful alternative is
offered through the development of mAbs directed
against the RV glycoprotein (37, 38). To overcome the
short supply of RIGs, the WHO Rabies Collaborating
Centres previously set out to investigate several mAbs
for inclusion into an antibody cocktail (6, 35). In a
WHO consultation in 2002, the mAbs 62-71-3, E559,
1112-1, D8, M777, and M727 were initially proposed
(35). mAb 1112-1 was eventually excluded because of
intellectual property reasons (6), and mAb D8 was
excluded due to insufficient strain coverage (unpub-
lished results). The remaining mAbs were shown to
target the same epitope on the viral glycoprotein,
namely antigenic site II, with the exception of mAb
62-71-3 (6). Three novel antibody cocktails were de-
signed, all containing mAb 62-71-3 as an essential
component (6).
In the present study, we report the cloning of a
chimeric IgG version of mAb 62-71-3 and expression in
a plant system. Initially, a phage-displayed scFv version
of mAb 62-71-3 was produced and tested for its neutral-
izing potency against a rabies pseudotype virus. This
step confirmed that the variable region sequences
correctly encoded for an antibody with neutralizing
potency toward the virus. A full-length chimeric anti-
body was then cloned and expressed in N. benthamiana.
The expression levels of mAb 62-71-3 were estimated by
quantitative ELISA and yielded 3–4% of total soluble
protein. This is 100 mg/kg fresh tissue weight. Al-
though these expression levels were satisfactory for the
current study and do not necessarily require any addi-
tional improvements for large-scale production, further
enhancement of expression would be desirable and
might be achieved by codon-optimization and by using
different expression vectors (two strategies that we are
currently further investigating for mAb 62-71-3).
The original murine 62-71-3 IgG was converted here
into a chimeric mAb with human antibody constant
region sequences in order to improve half-life and
reduce immunogenicity in humans. The resulting chi-
meric 62-71-3 IgG was shown to bind to its antigen in a
functional ELISA and to neutralize a rabies pseudotype
virus, confirming correct assembly and functionality of
the antibody. We also confirmed the neutralizing activ-
ity of the plant-derived mAb in the FAVN assay and
observed strong RV neutralization (500 IU/mg), simi-
lar to the previously reported potency of its murine
hybridoma-derived counterpart (6).
To further corroborate the strong neutralizing po-
tency by the plant-derived purified mAb 62-71-3, a
panel of different pseudotype viruses was tested. Several
lyssavirus pseudotypes were strongly neutralized, with
Figure 5. Competition ELISA. Saturating amounts of unla-
beled plant-derived mAbs (62-71-3 or E559) or no mAb ()
were allowed to bind to RV glycoprotein before addition of
biotinylated hybridoma-derived competitor E559. Binding is
expressed as the percentage of the binding of the biotinylated
antibody alone.
TABLE 3. Alignment of antigenic site I residues of the tested
lyssaviruses
Strain Neutralization Site I
CVS (RV)  KLCGVL
ERA (RV)  KLCGVL
RV131 (DUVV)  RLCGIS
SA06 (DUVV)  RLCGIS
RV9 (EBLV1)  RLCGVP
RV20 (EBLV1)  RLCGVP
RV1787 (EBLV2)  KLCGIS
RV634 (ABLV)  KLCGIS
Irkut  KLCGMA
Aravan  KLCGVM
Khujand  KLCGVS

See Fig. 3. Asterisks below alignments indicate conserved resi-
dues. Neutralization:  indicates complete (100%) neutralization; 
indicates that 100% neutralization could not be determined.
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the exception of two Duvenhage strains (SA06 and
RV131) and two European bat lyssavirus type 1 strains
(RV9 and RV20). These results are also consistent with
previous observations of mAb 62-71-3 produced in
hybridoma cells (6), which suggested that the hybrido-
ma-derived mAb broadly neutralizes different geno-
types but is ineffective at neutralizing the genotypes
Duvenhage virus and European bat lyssavirus type 1.
The purified recombinant mAb was then subjected
to mass spectroscopy and was shown to be glycosylated
with typical plant complex glycan structures. Although
mammalian and plant cells share similar cellular ma-
chinery for antibody assembly, their post-translational
modifications, including the processing of glycans, are
not completely identical. While the processing in the
ER is conserved among all eukaryotic species and is
restricted to oligomannose type N-glycans, the process-
ing in the Golgi varies between species, resulting in
differences between plant-derived proteins and their
mammalian counterparts (39). Plant glycans usually do
not contain sialic acid residues and may contain (1,2)-
xylose residues attached to the 	-linked mannose of the
glycan core and 	 (1,3)-fucose residues linked to the
proximal N-acetyl-glucosamine (40, 41). While it can-
not be excluded that these plant-specific glycans may
potentially be antigenic or allergenic in humans (42),
the glycosylation of plant-derived antibodies does not
seem to interfere with successful passive antibody ther-
apy (43, 44).
Competition experiments with biotinylated mAb
E559 demonstrated that mAb 62-71-3 does not depend
on antigenic site II, the immunodominant epitope in
mice. To shed more light on the antibody-antigen
interaction, a mutational analysis of the RV glycopro-
tein was undertaken. Lafon et al. (45) initially proposed
an antigenic structure for the RV glycoprotein, defining
several major epitopes. Antigenic site I has been de-
fined as an epitope complex between residues 226 and
231 (46, 34), originally identified using a single mAb,
which binds to an epitope, including residue 231 within
antigenic site I (45, 46). Antigenic site II comprises a
discontinuous epitope, including residues 34–42 and
residues 198–200 (47). This antigenic site is targeted by
most murine antibodies and mutations within these
residues can result in heavily reduced pathogenicity of
the virus (47). Antigenic site III comprises residues
330–338 and harbors two charged residues, K330 and
R333, which are linked to viral pathogenicity and
neuroinvasion (48, 49). Antigenic site IV contains over-
lapping linear epitopes with key residues 251 and 264
(50, 51). In addition, a few minor epitopes have been
identified, e.g., between residues 342 and 343 (minor
site a) and between residues 14 and 17 (45, 52).
Most studies on the antibody epitopes within the RV
glycoprotein have been undertaken by sequencing viral
escape mutants or by competition assays (53, 54). A few
other studies have relied on investigating the interac-
tion between antibodies and peptides derived from the
viral glycoprotein, e.g., peptides derived by cleaving the
glycoprotein with cyanogen bromide (55), short pep-
tides expressed in yeast (56), as well as synthetic pep-
tides for PEP-SCAN experiments (34). In the present
study, we made use of pseudotype viruses containing
chimeric RV/LBV glycoproteins generated by swapping
the antigenic sites of RV strain CVS11 (phylogroup I
lyssavirus) with those of LBV strain Nig56-RV1 (phylo-
Figure 6. Mutational analysis of the RV glycoprotein using the E. coli-derived 62-71-3 scFv and the plant-derived 62-71-3 IgG. A)
Phage-displayed 62-71-3 scFv was tested against a set of pseudotype viruses containing either the CVS11 wild-type glycoprotein
(CVS control) or mutated CVS11 glycoproteins containing the antigenic sites of LBV (LBV site I/II/III/IV) within the CVS
backbone. B) Plant-derived mAbs 62-71-3 and E559 and a nonspecific mAb were tested regarding their neutralization of
pseudotype viruses containing either the CVS11 wild-type glycoprotein or a mutated CVS11 glycoprotein containing LBV
antigenic site I (aa 226–231). C) Role of antigenic site I residue K226 was investigated by testing the plant-derived mAbs 62-71-3
and E559 regarding their neutralization of pseudotypes containing glycoproteins with a K226R mutation. Controls included
pseudotypes containing the CVS11 wild-type glycoprotein (CVS control) or containing the CVS glycoprotein containing a
nonspecific mutation within antigenic site III (N336S control). D) Neutralization of a site I mutant containing a G229E mutation
by mAbs 62-71-3 and E559.
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group II virus). It is well established that neutralizing
antibodies (including mAb 62-71-3) targeting phylo-
group I viruses are not effective at neutralizing phylo-
group II viruses (57, 58). The neutralization assays
indicated that virus neutralization by the 62-71-3 scFv
and the plant-derived 62-71-3 IgG specifically involve
antigenic site I.
To examine more closely how differences in anti-
genic site I residues account for the differences in
neutralization observed with different lyssavirus pseu-
dotypes, their glycoprotein sequences were compared.
The alignment revealed diverse antigenic site I residues
of lyssaviruses belonging to phylogroup I and related
Eurasian lyssaviruses (59–61). Although lyssaviruses
containing the antigenic site I residue K226 (lysine)
were completely neutralized by mAb 62-71-3, lyssavi-
ruses containing the residue R226 (arginine) demon-
strated diminished neutralization. To obtain further
insight into the role of antigenic site I residues K226 or
R226, we tested the 2 plant-derived mAbs 62-71-3 and
E559 regarding their neutralization of pseudotypes
containing glycoproteins with a K226R mutation. These
experiments corroborated the critical role of K226 for
neutralization by mAb 62-71-3. Moreover, pseudotypes
containing a G229E mutation, which has previously
been found in viral escape mutants resistant to a mAb
targeting antigenic site I (34), showed diminished
neutralization.
Previous studies indicated that mAb 62-71-3 was able
to neutralize viral escape mutants of mAb E559 (di-
rected against site II; ref. 6), similar to another mAb
(mAb D1) known to target antigenic site III. This
observation led the researchers (6) to suggest that mAb
62-71-3 targets an epitope different from antigenic site
II, possibly antigenic site III, as it is well established that
the vast majority of mAbs bind to sites II or III (48).
Unfortunately, no viral escape mutants could be gen-
erated for mAb 62-71-3 in vitro (6), so that its epitope
has been unknown so far. While this previous study (6)
already suggested that the epitope of mAb 62-71-3 does
not overlap with the epitope (site II) of mAb E559, our
present study provides the first systematic epitope anal-
ysis. Relatively few antibodies specific for antigenic site
I have been described to date (47, 59), and the neu-
tralization assays undertaken in our current study dem-
onstrate that antigenic site I, including residue K226 is
critical for neutralization mAb 62-71-3. The demonstra-
tion of the binding specificity of mAb 62-71-3 to the RV
glycoprotein at a molecular level provides an important
rationale for including mAb 62-71-3 in RV-neutralizing
antibody cocktails. The results provided here also indi-
cate that mAb 62-71-3 would be a particularly good
complement to antibodies targeting site II, such as mAb
E559, and that mAbs specific to site III could now also
be considered for inclusion in an antirabies cocktail
product.
The neutralization experiments with pseudotypes
containing mutated glycoproteins cannot differenti-
ate between direct and indirect effects, i.e., it is
currently not clear whether the diminished neutral-
ization observed with pseudotypes harboring site I
mutations is due to the absence of the targeted
epitope or due to indirect/allosteric effects (i.e.,
certain amino acid residues in site I might mask
neighboring epitopes that might be the real target of
mAb 62-71-3). Nevertheless, our results explain why
mAb 62-71-3 is relatively ineffective at neutralizing
certain genotypes, in particular, those belonging to
phylogroup II. Notably, many of these particular
genotypes have very little clinical relevance, so the
lack of neutralization of these genotypes does not
pose a significant problem in the further develop-
ment of the plant-derived mAb 62-71-3.
Future work should now focus on the evaluation of
additional mAbs regarding their potential to comple-
ment mAb 62-71-3. The development of a combina-
tion of mAbs targeting distinct, nonoverlapping
epitopes and covering a broad panel of RV isolates
would be highly desirable. This study has focused on
the molecular characterization of mAb 62-71-3, but
two other features of this study targeted facilitating
the clinical development of this antibody. First, we
have focused on the partial humanization of mAb
62-71-3. Although using a murine mAb in PEP is not
contraindicated, the use of human sequences is
generally preferred. Second, we have explored a
powerful plant expression system to generate the
recombinant mAb. For almost 2 decades, the poten-
tial of plants for production of mAbs has been
proposed (62). Recent advances in regulatory ap-
proval of plant biotechnologies and manufacturing
scaleup now take this potential much closer to reality.
There is now a real prospect of producing mAbs for
rabies PEP in plants to exploit low costs, massive
scalability, and potential technology transfer to re-
source-poor regions where rabies affects low-income
families.
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